Lichen Sclerosus Treatment Market is Segmented By Product Type (Injection, Creams/Ointment/Gel (Clobetasol, Fluocinolone, Synalar, Dermovate, Others), Others, By Mode of Administration (Topical, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Lichen Sclerosus Treatment Market is growing at a high CAGR 7.9% during the forecast period (2023-2030).
Lichen sclerosus is a skin condition that affects the vaginal and anal regions. They may, however, form on the upper body, such as the arms and breasts, in severe cases. According to several research, lichen sclerosus is most prevalent in females (after menopause), uncommon in adult males, and extremely rare in youngsters. Lichen sclerosus shows as white spots on the affected areas, which can be glossy and smooth and can grow into larger patches if left untreated. In addition, lichen sclerosus can cause red or purple bruises and increased tearing, itching, and bleeding. The exact cause of lichen sclerosus is unknown, however, it is thought to be caused by hyper-immunity or hormonal imbalance.
As per DataM Intelligence, Lichen Sclerosus Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Lichen Sclerosus Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Lichen Sclerosus Treatment Market in the United States and Canada produces the utmost share. Whereas the European Lichen Sclerosus Treatment Market is projected to continue its presence globally during the period of 2022- 2029.
Lichen Sclerosus Treatment Market Dynamics
The market for lichen sclerosus treatment has grown significantly over the last decade, owing to increasing number of female reaching menopause phase , increasing prevalence of skin diseases.
Increase in number of women with menopause will drive the market growth
The increasing frequency of immune system illnesses, particularly in females, drives the expansion of the lichen sclerosus therapy market. Furthermore, hormonal imbalance is a common symptom in women going through menopause, and they are more likely to acquire lichen sclerosus, which enhances the lichen sclerosus market. According to the United Nations, 985 million women aged 50 and up in the world.By 2050, the figure is expected to rise to 1.65 billion." "An estimated 6,000 women in the United States reach menopause every day (more than 2 million per year)." "By 2026, it is estimated that nearly one-quarter (22%) of the Canadian population will be made up of women over the age of 50." (Source: National Academy of Medical Sciences). It is estimated that around 13 million women in the UK are currently peri or menopausal (Wellbeing of Women) – that is one-third of the entire UK female population."
High susceptibility to pathogenic microorganisms is one of the main factors driving the growth of the lichen sclerosus treatment market. During the forecast period, the lichen sclerosus treatment market is expected to increase at a healthy rate. Treatment is not generally required based on the location, such as the upper body part; consequently, patches fade away after a period of time; nevertheless, if lichen sclerosus arises in the genital area, treatment is required. Patches become bigger if left untreated, causing discomfort during sex, urination, and other activities. Furthermore, lichen sclerosus has the potential to evolve into skin cancer over time. Because there are no exact treatment options for lichen sclerosus, the whole lichen sclerosus therapy industry offers profitable prospects for manufacturers and investors. Furthermore, very few industries are involved in developing or selling lichen sclerosus treatments, which creates an opportunity for third-party investors to enter the lichen sclerosus treatment industry.These factors are likely to boost the Lichen Sclerosus Treatment market.
The lack of a correct treatment is likely to hamper the market growth
The majority of people believe that lichen sclerosus is a common infection that can be treated on its own. Other obstacles, such as the lack of a correct treatment or a precise drug formulation for treating lichen sclerosus, can stymie the growth of the lichen sclerosus treatment market.
COVID-19 Impact Analysis
The lichen sclerosus treatment market shrank dramatically during the COVID-19 outbreak. The pandemic has made it more difficult to bring new treatments to market to gain market share or meet sales targets. Marketing outlets aren't as powerful as before the outbreak, save from new diagnoses and regimen switching. COVID-19 programming continues to dominate the few available channels. COVID-19 has slowed clinical trials, particularly those in the early phases. Researchers frequently could not obtain data remotely when traditional study sites closed, and many patients became less inclined to participate. Some therapeutic fields were very badly affected. While some development time can be made up, concerns have been raised about resource allocation and digital technology expenditures to keep trials operating now and in the future.
Lichen Sclerosus Treatment Market Segment Analysis
The creams segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Creams/Ointment/Gel will dominate the global lichen sclerosus treatment and is expected to continue during the forecast period. The growing burden of immune disorders disease and its deaths creates a need for treatment , which drives the market growth. For example, according to the National Institutes of Health, an autoimmune illness affects up to 23.5 million Americans (almost 7% of the population), and the number is growing.
Furthermore, market growth is fueled by introducing new products into the market. For example, in March 20 ,2020 Lupin introduced the USP Betamethasone Dipropionate Ointment (Augmented) .As a result, various market players' number of regulatory authority approvals for products is boosting the market growth.
Lichen Sclerosus Treatment Market
|
Metrics |
Details |
|
Market CAGR |
7.9% |
|
Segments Covered |
By Product Type, By Mode of Administration, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Lichen Sclerosus Treatment Market Geographical Analysis
North America region holds the largest market share of the global lichen sclerosus treatment market
North America has the greatest market share because of increasing awareness about reproductive healthcare and menopausal diseases ,more sophisticated healthcare infrastructure and greater availability of treatment alternatives, other factors, such as favorable reimbursement policies, also contribute to the growth of the North American lichen sclerosus treatment market. North American region is developing novel treatment and diagnostic methods. In August 2018, Lupin has introduced Clobetasol Propionate Cream USP 0.05 percent in the United States. Furthermore, rising death rates increased patient awareness of the availability of new lichen sclerosis treatment procedures. Advanced healthcare infrastructure is expected to drive the growth of the lichen sclerosus treatment market in North America.
Lichen Sclerosus Treatment Market Competitive Landscape
The lichen sclerosus treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Tiefenbacher API, Dayaram Pharma, Akhil Healthcare, Wellona Pharma, Aarti industries, Manus Aktteva, Medimetriks, LGM Pharma, Global Pharma, Teva, among others.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the lichen sclerosus treatment market globally. For instance, In February 2019, Mylan introduces WixelaTM InhubTM (fluticasone propionate and salmeterol inhalation powder, USP), the first generic version of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a list price that is 70% less than the brand.
Medimetriks Pharmaceuticals
Overview:
Medimetriks Pharmaceuticals, Inc. is a pharmaceutical company. The business specializes in developing prescription skincare brands for acne, atopic dermatitis, fungal infections, dystrophic nails, impetigo, and testing and delivery services.
Product Portfolio:
Synalar: The composition is gentle and water-washable, making it excellent for use on the face and other delicate regions.Specifically created for patients with sensitive skin.Sulfate-free
Ideal for the treatment of dermatoses with water-soaked lesions.Topical steroid of class 5
